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Abstract
In this study, we apply State Dependent Riccati Equation (SDRE) based optimal control technique to a
nonlinear tumor growth model. The model consists of three biological cells which are normal tissue, tumor
and immune cells. The eﬀect of chemotherapy treatment is also included in the model. Chemotherapy administration is considered as a control input to the nonlinear cancer dynamics and the amount of administered
drug is determined by using SDRE optimal control. The optimal control is applied to the model in order
not only to drive the tumor cells to the healthy equilibrium state but also to minimize the amount of the
drug used. In SDRE control design, we investigate the eﬀects of diﬀerent weighting matrices in the cost
function to be minimized. Simulation results show that selection of state dependent weighting matrices can
yield positive outcomes such as less drug administration or control of tumor growth in a shorter time period.
Key Words: Cancer, tumor growth, cancer model, SDRE control

1.

Introduction

Although many improvements have been obtained in the treatment of cancer, most cancer types are still
incurable due to the non-responsiveness of the tumor cells to therapy, the relapse characteristics of the tumor
cells, the toxicity limitations of the treatments, insuﬃcient dose administration and inaccurate scheduling, etc.
Development of treatment strategies requires many clinical experiments ﬁrst on animals and then on humans
in order to ﬁgure out a convenient way for the administration of the therapy. These experiments, in general,
take a long time, increase the treatment costs and most importantly, may result in many deaths during the
development period. Clinical experiments also reveal the fact that there is a strong relationship between the
cancer state (the number and/or volume of tumor cells, tumor type), the immune system of the patient and
the treatment strategy [1, 2]. Hence, understanding the dynamical behavior of cancer has been of great interest
not only to the clinical scientist but also to the mathematicians, physicists and engineers.
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Mathematical models of tumor growth have been used by the scientists in order to analyze the growth
dynamics and to develop treatment strategies by using diﬀerent mathematical control methods [3–10]. Depending on the patient’s immune system and cancer type, diﬀerent mathematical models are proposed some of
which are validated with experimental results. These models are then incorporated into a proposed treatment
strategy such as chemotherapy, immunotherapy, and radiotherapy (in some cases, combined therapies are also
suggested). In general, the eﬀect of the therapy is added to the mathematical models of tumor growth as a
control input. The dynamics of cancer have a complex nature and the corresponding mathematical models are
illustrated with nonlinear systems of diﬀerential equations. As a result, applications of linear control strategies
to the nonlinear models, in general, fail. Linearization of the models, on the other hand, can cause undesirable
outcomes such as uncontrolled spread of cancer or toxicity eﬀects which may have a negative eﬀect on the
patients’ lives or cause detrimental side eﬀects to healthy organs. Therefore, therapy administration for the
cancer is handled as a nonlinear control problem which is to be solved such that tumor level is decreased and a
healthy immune system is ensured during the treatment progress.
It is stated that optimal administration of the therapy can increase the survival chance in cancer treatment
[11, 12]. Various applications of optimal control to speciﬁc type or non-speciﬁc type cancer models have been
investigated by diﬀerent researchers [4, 7, 8, 13–15]. The techniques used in the literature to solve optimal control
problems for nonlinear systems (in particular, cancer models which are highly nonlinear and high dimensional)
are carefully addressed to have an optimal solution and the solution methods cannot be generalized due to the
special computational eﬀorts to obtain them. A new optimal control method for cancer treatment is suggested
in [16], in which Linear Time Varying (LTV) approximations of the nonlinear cancer dynamics are used. The
nonlinear cancer dynamics is approximated as a sequence of LTV models whose limit behavior converges to
the behavior of the nonlinear cancer dynamics. This approach enables one to design the optimal controller for
LTV approximations by using the well-known Linear Quadratic Regulator (LQR) techniques. Although the
method gives globally valid results by recursively solving an inﬁnite series of LQR problems for LTV systems,
because of its recursive nature, it is an oﬀ-line method which requires pre-computation of the optimal control
eﬀorts. On the other hand, other common control techniques for nonlinear system such as feedback linearization,
sliding mode control, gain scheduling, and adaptive control require strong conditions on the system [17]. One
of the main issues in these control techniques is that they are not completely suﬃcient for drug administration
problems since optimality is required to minimize a desired cost functional.
A recently developed technique which does not yet have complete theoretical background is called State
Dependent Riccati Equations (SDRE) based optimal control and has been applied successfully to nonlinear
systems both in theory and experimental practice [18–20]. Although there are some applications of SDRE
optimal control to biological systems [21], control of drug administration in cancer dynamics using this method
has not been studied yet. Due to its computational simplicity and its satisfactory simulation/experimental
results, SDRE optimal control technique becomes an attractive control approach for a class of nonlinear systems
and therefore many research and application results are reported (see [22] and the references therein).
In this study, we suggest SDRE based optimal control for the nonlinear cancer dynamics by extending
our previous results presented in [23]. The drug administration in the cancer treatment is an optimal control
problem which is deﬁned as the minimization of drug amount and duration of the treatment. In this work,
the amount of chemotherapy drug administration is considered as a control input to the system which holds
the interactions between normal, tumor and immune cells. The aim of the control is to eradicate the tumor
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cell population whilst minimizing the amount of chemotherapy. The cost functional for the optimal control
is selected as a quadratic function of the states and control which is biologically relevant. One of the main
contributions of this paper is to apply SDRE optimal control to cancer dynamics. Although there are many
optimal control algorithms proposed in this ﬁeld, almost all of these algorithms require the use of some special
nonlinear optimization software. Unlike the other optimal control approaches which have appeared in the
literature in which (Hamilton-Jacobi-Bellman) HJB equations should be solved by using numerical shooting
methods or using special nonlinear optimization algorithms, the method proposed here gives a sub-optimal
solution by solving the well-known linear quadratic regulator (LQR) problem. The method also gives some
extra freedom in order to choose diﬀerent state dependent coeﬃcient (SDC) matrices and weighting matrices of
the states and controls which may lead to better results in terms of chosen variables such as a state or a control
input.
The method suggested in this paper diﬀers from [16] in many senses, such as in its control structure
and applications. In terms of the control structure, SDRE uses frozen Linear Time Invariant (LTI) models of
the nonlinear dynamics at each time whereas LTV approximations are used in [16]. The results of these two
diﬀerent control approaches cannot be compared since the SDRE one gives the time responses of the nonlinear
system directly but the method proposed in [16] gives only recursive approximations, whose converged values
are the results of the nonlinear dynamics. Therefore SDRE method may be implemented on-line by using fast
microprocessors in the controller structure, however the method proposed in [16] is an oﬀ-line method by nature.
The paper is organized as follows. a brief background for SDRE control design is introduced in Section
2. Section 3 represents the nonlinear cancer model with and without chemotherapy eﬀect. The optimal control
approach is summarized and diﬀerent system representations are given. In section 4, we give the simulation
results for SDRE based control of the tumor growth model. Finally, conclusions are drawn.

2.

SDRE control outline

The optimal control problem of dynamical systems has been studied in theory for a given cost functional to be
minimized. The solution of this problem is well-established for Linear Time Invariant (LTI) systems subjected
to a linear quadratic functional. Mainly, the solution of Algebraic Riccati Equations (ARE) produces necessary
information to compute the optimal feedback gain(s). Hence, the regulation (stabilization) problem of LTI
systems, which is known as LQR (Linear Quadratic Regulator), is solved in optimal way.
The optimal control for nonlinear systems, on the other hand, cannot—in general—be handled in a
way similar to LTI systems as the solutions of Hamilton Jacobi Bellman (HJB) equations do not yield a
straightforward procedure. Analytical solutions for the optimal control may be obtained for only a few restricted
cases since the governing equations for optimality are also nonlinear and their solutions should satisfy the
terminal conditions. It is well known [24] that even numerical solutions for the optimal control cannot be
obtained with precision for nonlinear systems as the number of possible candidates for the optimal solution is
not known. This diﬃculty brings out many diﬀerent approaches to approximate solutions to the HJB equation
which are regarded as suboptimal solutions to the optimal control problem of nonlinear dynamical systems.
One of the approaches to the optimal control of nonlinear systems is the use of the SDRE technique. The
method, which gives a systematic way of designing nonlinear feedback controllers that approximate the solution
of the inﬁnite time horizon optimal control problem, is described in detail in [18, 19]. The method is based
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on the so-called pseudo-linearized or extended linearized form of the nonlinear system in which the nonlinear
system is treated as a sequence of LTI systems. Then the suboptimal solution is computed via solving the ARE
for the LTI systems obtained in each time step. The nonlinear system to be considered in this study is
ẋ = f(x) + G(x)u,

(1)

where x ∈ Rn and u ∈ Rm . System (1) can be represented in the pseudo-linear form
ẋ = A(x)x + B(x)u,

(2)

where f(x) = A(x)x and G(x) = B(x). In equation (2), A(x) ∈ Rn×n and B(x) ∈ Rn×m are state dependent
coeﬃcient (SDC) matrices which bring the nonlinear system described by (1) into a linear-like representation.
It is known that SDC parameterization of the nonlinear system is not unique; however, among the alternatives,
the chosen parameterization should yield point-wise controllability to design the SDRE control law [18]. To
ensure the point-wise controllability condition, the so-called “state dependent controllability matrix”


(3)
M (x) = B(x) A(x)B(x) · · · An−2 (x)B(x) An−1 (x)B(x)
must have full rank for the domain for which the nonlinear system is controlled.
It is clear that after the parameterization, the nonlinear system representation given by equation (2)
resembles the ẋ = Ax + Bu LTI form apart from SDC matrices A(x) and B(x). The aim of the SDRE control
is to determine the sub-optimal controller for the system (2) such that the following cost functional is minimized:
1
J=
2

∞
(xT Q(x)x + uT R(x)u)dt.

(4)

0

Here, Q(x) ∈ Rn×n and R(x) ∈ Rn×m are state dependent weighting matrices which satisfy Q(x) ≥ 0 and
R(x) > 0 for ∀x . Some optimal control problems require constraints on the system states and/or control input
to be satisﬁed. The selection of the weighting matrices Q(x) and R(x) as state dependent may play important
role on satisfying the requirements of the optimal control problem. On the other hand, one can impose hard
bounds on the control by penalizing the Hamiltonian [21]. The Hamiltonian for the optimal control problem is
given by
H(x, u, λ) =

1 T
(x Q(x)x + uT R(x)u) + λT (A(x)x + B(x)u) − w̄ T (u − umin ) − ŵ T (umax − u),
2

(5)

where w̄ and ŵ are non-negative m dimensional penalty multiplier vectors. They are introduced to impose the
constraints on the control inputs and must satisfy the conditions
w̄ T (u − umin ) = ŵ T (umax − u) = 0.

(6)

From the Hamiltonian the necessary conditions for optimality are
ẋ =

∂H
∂λ

= A(x)x + B(x)u





dA(x)x T λ − dB(x)u T λ .
=
−Q(x)
−
λ̇ = − ∂H
∂x
dx
dx
0=
718
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= R(x)u + B T (x)λ − w̄ + ŵ
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The last equation of Equation (7) gives the optimal control of the form


u(x) = −R−1 (x) B T (x)λ − w̄ + ŵ .

(8)

By applying the theory of LQR, the ad-joint state vector has the form given by
λ = P (x)x,

(9)

where P (x) ∈ Rn×n is a symmetric state dependent matrix. The sub-optimal control for the nonlinear system
with bounded control input is obtained as
u(x) = min(max(ũ, umin ), umax),

(10)

where umin and umax are the minimum and maximum bounds on the control, respectively, and the unbounded
control is obtained as
ũ(x) = −R−1 (x)B T (x)P (x)x,
(11)
which is a feedback control with the feedback gain matrix of K op (x) = R−1 (x)B T (x)P (x). The symmetric,
positive deﬁnite matrix P (x) is obtained from the solution of algebraic Riccati equation given by the relation
AT (x)P (x) + P (x)A(x) − P (x)B(x)R−1 (x)B T (x)P (x) + Q(x) = 0.

(12)

In order to solve (12), the pair (A(x), B(x)) must be point-wise controllable ∀x. Dynamics of the closed-loop
system is now illustrated by the relation
ẋ = (A(x) − B(x)K op (x))x = ACL (x)x.

(13)

Local asymptotic stability of the closed-loop system is proved in both [18] and [19] and stated in the following
theorem.
Theorem [19] Assume that the system
ẋ = f(x) + B(x)u
is such that f(x) and

∂f(x)
∂xi

i=



1, · · · n



are continuous in x for all x ≤ r, r > 0 , and that f(x)

can be written as f(x) = A(x)x (in SDC form). Assume further that A(x) and B(x) are continuous and the
system deﬁned by (2) and (3) is a detectable and stabilizable parameterization in some nonempty neighborhood
of the origin Ω ⊆ Br (0). Then the system with the control given by (11) is locally asymptotically stable.
The design of SDRE control is then based on the freezing of the nonlinear system which is represented
in pseudo-linear form, and application of linear quadratic regulator (LQR) control to the linear systems in each
time step. The state dependent quadratic cost functional is minimized at each time step and the feedback
control is then applied to the nonlinear system.

3.

Mathematical model of the tumor growth

Mathematical models for cancer dynamics have been studied by many scientists using diﬀerent mathematical
methods. Some of these models consider the growth of tumor cells as population dynamics problems which
719

Turk J Elec Eng & Comp Sci, Vol.18, No.5, 2010

include the interaction of tumor cells with other cells (e.g. normal cells and immune cells). In order to develop
treatment strategies, the eﬀects of therapy are also included in the models as control inputs. In this study,
we analyze the model originally discussed in [4]. The model does not aim to concentrate on a speciﬁc kind
of cancer and uses normalized parameters. It includes three diﬀerent cell populations and chemotherapy drug
concentration. Interaction of the tumor cells with normal and immune cell population in the absence of any
treatment is given by the system
Ṅ = r2 N (1 − b2 N ) − c4 T N,
Ṫ = r1 T (1 − b1 T ) − c2 IT − c3 T N,
I˙ = s +

ρIT
α+T

(14)

− c1 IT − d1 I.

where N (t), T (t) and I(t) denote the number of normal cells, the number of tumor cells and the number
of immune cells at time t, respectively. The ﬁrst term in the normal cell population is the logistic growth of
normal cell population with growth rate r2 and maximum carrying capacity b−1
2 . The second term is the loss
of normal cells due to competition among tumor-normal cells for local resources. In a tumor cell population,
the ﬁrst term denotes the logistic growth of tumor cells in the absence of immune surveillance with the growth
rate r1 and maximum tumor carrying capacity b−1
1 . The second and the third terms are death terms for tumor
cells due to the interaction between immune and normal cells, respectively. Immune cells have a constant source
s which can be supplied from bone marrow or lymph nodes, etc. In the presence of tumor cells, immune cells
are stimulated by tumor cells with a Michaelis-Menten type saturation function with the positive parameters ρ
and α . Immune cells are deactivated by tumor cells at the rate c1 and they also die at the natural death rate
d1 .
There are diﬀerent ways to include the eﬀect of chemotherapy in the tumor growth model. We assume that
chemotherapy kills all cell populations with diﬀerent ratios using mass action term. The eﬀect of drug therapy
in the model is shown with an additional state M (t) and control input u(t) which denote drug concentration
in the blood stream, and external drug injection respectively. The nonlinear system with the eﬀect of drug
therapy is
Ṅ = r2 N (1 − b2 N ) − c4 T N − a3 M N,
Ṫ = r1 T (1 − b1 T ) − c2 IT − c3 T N − a2 M T,
I˙ = s +

(15)
ρIT
α+T

− c1 IT − d1 I − a1 M I,

Ṁ = −d2 M − u(t).
Here, a1 , a2 , and a3 are the diﬀerent killing eﬀects of chemotherapy on the cell populations. Chemotherapy drug
decay rate in the blood stream is denoted by d2 . The system parameters which are normalized to the maximum
carrying capacity of the normal cells are given in Table 1. Analysis of the model for possible equilibrium points
in the absence of therapy is given in the next sub-section.
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Table 1. Model parameters.

Parameter
a1
a2
a3
b−1
1
b−1
2
c1
c2
c3
c4
d1
d2
r1
r2
s
α
ρ

3.1.

Description
Fractional normal cell kill by chemotherapy
Fractional tumor cell kill by chemotherapy
Fractional immune cell kill by chemotherapy
tumor cell carrying capacity
Normal cell carrying capacity
Fractional tumor cell kill by immune cells
Fractional immune cell kill by tumor cells
Fractional tumor cell kill by normal cells
Fractional normal cell kill by tumor cells
Death rate of immune cells
Decay rate of chemotherapy drug
tumor cell growth rate
Normal cell growth rate
Steady source rate for immune cells
Immune threshold rate
Immune response rate

Value
0.05
0.15
0.1
1.0
1.0
1.0
0.5
1.0
1.0
0.2
1.0
1.5
1.0
0.33
0.3
0.01

Analysis of the model

In the absence of therapy, equilibrium points of the system can be obtained as follows:
Ṅ = 0 ⇒

Ṫ = 0 ⇒

N = 0,
N = b12 −

c4
r2 b2

(16)

T.

T = 0,
T =

I˙ = 0 ⇒ I =

1
b1

−

c2
r1 b1

I−

c3
r1 b1

N.

s(α + T )
.
(c1 T + d1 )(α + T ) − ρT

Ṁ = 0 ⇒ M = 0,

(17)

(18)
(19)

provided that ρT = (c1 T + d1 )(α + T ).
The system has three diﬀerent types of equilibria: Tumor-free (no tumor cells), Dead (no normal tissue
cells), and Coexisting (both normal and tumor cells exist) equilibrium points. Depending on the system
parameters given in Table 1, there could be zero, one, two, or three of these equilibria types [4]. In the
context of developing therapy strategy, Tumor-free or Coexisting type equilibrium points should be reached,
since in these types of states, the normal cell population is close to its healthy state. In this study, our aim
is to determine the therapy dosage to bring the system to the tumor-free equilibrium point. The tumor-free
equilibrium point of the system is obtained as (1/b2 , 0, s/d1, 0) which gives us a healthy normal cell population
of (1/b) and immune cell population of (s/d1 ) with zero tumor level and zero drug injection. The linearized
model around this equilibrium point has stable eigenvalues which are (−1, −0.325, −0.2, −1) for the given
parameter set in Table 1.
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One of the main issues in cancer treatment is the existence of periodic behavior; i.e., re-growth of the
tumor cells after the treatment. For the given mathematical model of the cancer dynamics, existence of possible
periodic orbits is explored in [4] in detail. In this study, we shall only refer to the following proposition.
Proposition [2]. All orbits of system (9), with the parameter set given in Table 1, with initial values in the
positive octant, have exactly one of the equilibria as their limit set. In particular, all orbits are bounded and the
system admits no nontrivial periodic orbits.

3.2.

SDRE optimal control and pseudo-linear representation of the system

There are various optimal therapy strategies for cancer treatment proposed in the literature [4, 8, 13–15].
Almost all of these methods aim at minimizing the amount of drug during the treatment period which also
results with the less toxicity eﬀect to the healthy tissues. Therefore, a cost functional is deﬁned in terms of
drug (input) and tumor cell population (state) and then an optimal solution is suggested which minimizes the
proposed functional. Nevertheless, the optimal drug administration is determined by using special computer
software, since the cost functional is minimized associated with the nonlinear dynamical equations. Moreover,
the existence of such an optimal control should be proved beforehand.
In this study, we apply the SDRE control method to the tumor model which requires no additional burden
both in proving the existence of an optimal control and in computing the necessary drug administration. We
use the classical LQR algorithm in the computation of optimal control. In order to implement SDRE based
optimal control, the system is deﬁned in the form of (2). We can rewrite the system by shifting the tumor-free
equilibrium point (1/b2 , 0, s/d1, 0) to the origin in terms of the following error states:
x1 = N −

1
, x2 = T,
b2

x3 = I −

s
,
d1

x4 = M,

(20)

T

where x = [x1 , x2 , x3 , x4 ] denotes error states. The system in the new coordinates is
ẋ1 = −r2 x1 (1 + b2 x1 ) −

−

c4
b 2 x2

ẋ2 = r1 x2 (1 − b1 x2 ) − ( cd21s +
ẋ3 = − cd21s x2 − d1 x3 −

a1 s
d1 x4

a3
b 2 x4

c3
)x2
b2

+

− c4 x 1 x 2 − a 3 x 1 x 4 ,

− c3 x 1 x 2 − c2 x 2 x 3 − a 2 x 2 x 4 ,

ρs
x2
d1 (α+x2 )

x2 x3
+ ρ (α+x
− c1 x 2 x 3 − a 1 x 3 x 4 ,
2)

(21)

ẋ4 = −d2 x4 + u(t).
The nonlinear system given by Equation (21) is now in the form of (1) which has equilibrium at the origin.
These systems can be represented in the form of pseudo-linear given by Equation (2).
One of the main diﬃculties in the SDRE control is the selection of SDC matrices, as the SDC representation is not unique and there is not a straightforward selection procedure for f(x) = A(x)x factorization.
In fact, this diﬃculty can be handled advantageously to get diﬀerent sub-optimal solutions provided that the
selected SDC matrices are point-wise controllable. However, one should note that the point-wise controllability
of the selected (A(x), B(x)) pair does not have any implication on the controllability of the nonlinear system
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[18, 22]. In this work, we use the following pseudo-linear representation for the system (21):
⎡
⎢
⎢
⎢
⎢
A(x) = ⎢
⎢
⎢
⎣

−r2 (1 + b2 x1 )

−c4 (x1 +

−c3 x2

r1 (1 − b1 x2 ) − ( cd21s +

0

ρ(x3 + ds )
1

(α+x2 )

0

1
b2 )

− c1 (x3 +
0

s
)
d1

0
c3
b2 )

− x4

−c2 x2
−d1
0

−a3 ( b12 + x1 )

⎤

⎥
⎥
⎥
⎥
⎥
⎥
−a1 (x3 + ds1 ) + x2 ⎥
⎦
−a2 x2

(22)

−d2

T

and B(x) = [0, 0, 0, 1] .
Note thatf(x) = A(x)x . In this work, the SDRE control is determined for the type quadratic cost
functional
∞
 T

J=
x Q(x)x + rC (x)u2 dt,
(23)
0

in which the weighting matrix Q(x) and control weighting rC (x) are state dependent. With the state dependent
weightings, it is possible to give more importance to some of the states or controls in the cost functional. This
freedom is another advantage of the SDRE control method.

4.

Simulations

The aim of the therapy is to kill the tumor cells whilst minimizing the amount of drug application, which also
reduces the possible detrimental toxicity eﬀect, caused by the excess usage of the chemotherapy drugs. In the
simulated cancer model, the healthy equilibrium point with the parameter set (1, 0, 1.65, 0) is locally stable,
which means that the growth of cancer is controllable if a suﬃcient immune surveillance is guaranteed. In the
absence of suﬃcient immune control, the tumor cells grow in number and kill the healthy tissue cells and reach
the limit capacity, which is referred to as dead equilibrium point. In our simulations, in order to avoid selfcontrol of the immune system on the cancer cells, we choose a scenario where the initial immune cell population
is very small and the tumor cell population is large, so that tumor growth is inevitable unless chemotherapy is
applied. The initial states, i.e., the conditions when the chemotherapy treatment is started, are assumed to be
(N (0) = 1, T (0) = 0.20, I(0) = 0.15, M (0) = 0). The response of treatment-free cancer growth with respect
to normalized time scale is given in Figure 1.
One of the most important issues in the optimal control is the selection of the cost functional to be
minimized. Usually systems give clues as to what the cost functional can be. In the optimal control application
to cancer models, there is not a certain selection of the cost [13]. Many authors have proposed diﬀerent cost
functionals which can consist of the number of tumor cells, the amount of drugs or their combination. In our
study, we select the weightings of the quadratic cost functional (3) as a combination of the number of tumor
cells and drug, which is biologically relevant. We simulate four diﬀerent cases of optimal control application
to the cancer model to show the eﬀects of diﬀerent weighting matrices as well as bounded control. Toxicity is
an important phenomenon is cancer chemotherapy as it reduces the patient’s health quality as well as causing
serious side eﬀects which can result in death. Hence in our simulations we discuss the cases where the control
input is unbounded and bounded to one unit drug (0 ≤ u ≤ umax = 1). Moreover, we try to keep the number
of normalized normal cell population above 0.75 to avoid the toxicity eﬀect of excess chemotherapy injection.
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Figure 1. Response of the system in the absence of control.

We now discuss the cases below to show the eﬀects of diﬀerent weighting matrices and bounded control.
Case 1: We use constant weighting matrices Q and R selected as follows:
⎡

0

0

⎢
⎢ 0 ω1
⎢
Q=⎢
⎢ 0 0
⎢
⎣
0 0

0

0

⎤

⎥
0 ⎥
⎥
⎥
0 0 ⎥
⎥
⎦
0 ω2

0

(24)

and R = rC ,
where ω1 ≥ 0, ω2 ≥ 0 and rC > 0 must be satisﬁed so that Q ≥ 0 and R > 0 . We select the parameters as
ω1 = 100, ω2 = 0.1 and rC = 1.2 in order to enable a comparison with the other cases. The cost functional
given by (3) becomes
∞


ω1 (x2 (t))2 + ω2 (x4 (t))2 + rC (u(t))2 dt.
(25)
J=
0

Here, x2 (t) refers to the number of tumor cells, x4 (t) is the drug concentration in the blood and u(t) is the
amount of drug given to the patient at time t. The controlled normalized states of the system for case 1 are
given by Figure 2.
Case 2: In this case we use the constant weighting matrix for states Q , given by (24), with the same parameters
as in case 1, and a state dependent weighting for control, R(x) = rC + γ0 x2 (t), where γ0 is a positive constant
and selected as γ0 = 10 . As it can be seen that at the beginning, R(x) is greater than rC , since x2 (0) > 0.
However as control is applied, the number of tumor cells decreases and R(x) tends to rC as x2 (t) → 0 . This
means that at the beginning of the treatment the weighting of the control will be high which provides less control
comparing to the constant weighting case. As x2 (t) → 0 , the weighting of the control decreases, resulting with
a higher control eﬀort to minimize the cost functional. The aim of selecting this type of R(x) is to reduce the
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toxicity eﬀects of high drug application at the beginning of the therapy. The controlled states are shown in
Figure 3 for case 2. The number of normal cells is obtained very close to the toxicity limit. Also, control is
lower than the bound.
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Figure 2.
Case 1: System response as a function of
time; Q and R are constant.
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Figure 3. Case 2: System response as a function of time;
R(x) = rC + γ0 x2 (t) .

Case 3: We use the same constant weighting matrix for states Q , given by (24) and a state dependent weighting
for control, R(x) = rC − γ1 x2 (t), where γ1 is a positive constant satisfying the condition rC > γ1 x2 (t). We
select γ1 = 5 so that R(x) > 0 . R(x) is less than rC at the beginning of the therapy, since x2 (0) = 0.20.
However as control is applied, the number of tumor cells decreases and R(x) tends to rC as x2 (t) → 0 . Initially
this selection of R(x) provides larger control values than the case of R = rC . As x2 (t) → 0 , the weighting of
the control increases resulting with a less control eﬀort to minimize the cost functional. The controlled states
are given in Figure 4. As it can be seen in Figure 4, this type of selection of R(x) causes toxicity problems
since much control eﬀort is applied to reduce the number of tumor cells and also, the bound condition of the
control is not satisﬁed.
Case 4: In this case we again consider the same weighting matrices of Case 1 with a limit on the control, i.e.
(u ≤ umax = 1). The response of the system to the applied control is shown in Figure 5. Since the bound
reduces the amount of drug application into the system, the number of normal cells is kept very close to 0.75.
We should note that imposing a bound on the control does not always satisfy the sub-optimality condition [21,
25].
We compare the amounts of drug injections in Figure 6. As it can be seen from the ﬁgure, while case 2
and case 4 satisfy the maximum control bound condition, case 1 and case 3 use larger amount of drug than the
maximum bound to control the tumor growth. For the sake of clarity of Figure 7, we limit the drug axes at 10,
although the amount of the drug for case 3 is obtained around 20 at the beginning of the simulation. In order
to show the toxicity eﬀect caused the drug application, we give a comparison of the number of normal cells in
Figure 7. As expected, high drug application causes more toxicity and results in the killing of more normal cells,
which also can be seen from the ﬁgure that Case 1 and Case 3 cannot satisfy the condition of biological limit
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for the normal cells. Figure 8 shows the change in the tumor cell population over time. Case 3 provides the
shortest time in driving the number of tumor cell to the healthy equilibrium point. This is followed by Case 1,
as expected, and the other cases give almost similar time for the eradication of cancer cells although there are
some perturbations in the cancer cell numbers during time. Therefore, selection of diﬀerent weighting matrices
can yield positive outcomes such as less drug administration or eradication of the tumor cells in a shorter time
period compared to some other alternative selections.
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Figure 4. Case 3: System response as a function of time;
R(x) = rC − γ1 x2 (t) .
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5.

Conclusion

We have developed an SDRE based optimal control and applied it to a model of cancer dynamics. We have
shown that SDRE optimal control method provides fast and easy derivation of sub-optimal control for the
chemotherapy administration problem. The eﬀects of diﬀerent state dependent weighting matrices to the SDRE
performance have been investigated. The results show that these features of the SDRE optimal control can
be advantageously used in the determination of drug administration in the simulated model. However, the
selection of SDC matrices and state dependent weightings does not have a straightforward design procedure.
Especially, how to select the system representation stays as an unanswered problem. On the other hand, besides
tweaking the controller parameters priori and applying ad-hoc “anti-windup” schemes a posteriori to satisfy the
constraints, there are other methods to impose constraints on the control problem in SDRE design [26]. We
have shown that we can satisfy the required constraints on the control problem by deﬁning state dependent
weighting matrices. As a future work, this technique could be applied to a quantitative cancer model which
uses real clinical parameters. Moreover, the computational advantage of the method can be used to design drug
scheduling.
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